CAS 154525-25-4

uroguanylin human

Description:

Uroguanylin is a peptide hormone that plays a crucial role in regulating fluid and electrolyte balance in the human body. It is primarily produced in the intestines and is involved in signaling pathways that influence renal function and blood pressure. Uroguanylin acts by binding to guanylate cyclase receptors, leading to an increase in intracellular cyclic guanosine monophosphate (cGMP) levels, which subsequently promotes natriuresis (the excretion of sodium in urine) and diuresis (increased urine production). This peptide is structurally similar to guanylin, another intestinal peptide, and both are part of the larger family of natriuretic peptides. Uroguanylin's physiological effects include modulation of gastrointestinal motility and enhancement of mucosal defense mechanisms. Its dysregulation has been implicated in various conditions, including hypertension and heart failure. The CAS number 154525-25-4 specifically identifies this peptide, facilitating its recognition in scientific literature and databases. Overall, uroguanylin is an important component of the body's homeostatic mechanisms, particularly in fluid regulation.

Formula: C₆₄H₁₀₂N₁₈O₂₆S₄

Synonyms:

• ASN-ASP-ASP-CYS-GLU-LEU-CYS-VAL-ASN-VAL-ALA-CYS-THR-GLY-CYS-LEU
• Uroguanylin Topoisomer A (human)
• asn-asp-asp-cys-glu-leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu [disulfide bridges: 4-12, 7-15]
• Uroguanylin >=90% (HPLC)
• UROGUANYLIN
• H-ASN-ASP-ASP-CYS-GLU-LEU-CYS-VAL-ASN-VAL-ALA-CYS-THR-GLY-CYS-LEU-OH
• UGN (HUMAN)
• L-Leucine, L-asparaginyl-L-α-aspartyl-L-α-aspartyl-L-cysteinyl-L-α-glutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, cyclic (4→12),(7→15)-bis(disulfide)
• ASN-ASP-ASP-CYS-GLU-LEU-CYS-VAL-ASN-VAL-ALA-CYS-THR- GLY-CYS-LEU(DISULFIDE BRIDGE: CYS4-CYS12, CYS7-CYS15)
• UGN (huMan)
• UROGUANYLIN (HUMAN)
• Uroguanylin (huMan)

Uroguanylin Topoisomer A (human)

CAS: 154525-25-4

Uroguanylin belongs to the guanylin family of cyclic guanosine monophosphate (cGMP) regulating peptides. This family of peptides shows homology to the heat stable enterotoxins produced by strains of Escherichia coli and other enteric bacteria that cause a secretory form of diarrhea. Along with the isolation of uroguanylin from urine and the subsequent demonstration of its natriuretic activity by direct effects on the kidney, uroguanylin has been suggested to play a role in the physiological maintenance of sodium balance in vivo. Uroguanylin activation of the guanylate cyclase-C/cyclic guanosine monophosphate pathway elicited analgesic effects in animal models of colonic hypersensitivity, unraveling a novel pathway to treat abdominal pain (Silos-Santiago et al. (2013)).

Formula: C₆₄H₁₀₂N₁₈O₂₆S₄

Purity: 92.7%

Color and Shape: White Powder

Molecular weight: 1667.88

Ref: 01-4030148

Uroguanylin (human)

CAS: 154525-25-4

Uroguanylin (human) serves as a natural ligand for the Guanylyl Cyclase C (GCC) receptor in metastatic colorectal cancer tumors and exhibits anti-tumor effects

Formula: C₆₄H₁₀₂N₁₈O₂₆S₄

Purity: 98%

Color and Shape: Solid

Molecular weight: 1667.86

Ref: TM-T80067

Uroguanylin (Human)

CAS: 154525-25-4

Uroguanylin (Human) product containing the disulfide bonds: Cys4-Cys12 and Cys7-Cys15 and avaialable in the trifluoroacetate salt form. Uroguanylin is a peptide hormone that is involved in the regulation of fluid and electrolyte balance in the body. It is produced in the intestinal tract, specifically in the lining of the small intestine and colon.
Uroguanylin belongs to a family of peptides that includes guanylin and the heat-stable enterotoxins (STs).These peptides all share a similar structure and function, as they bind to and activate the guanylate cyclase-C (GC-C) receptor in intestinal cells.
Activation of GC-C by uroguanylin leads to an increase in cyclic GMP (cGMP) levels, which in turn activates a variety of downstream signaling pathways. This leads to an increase in chloride and bicarbonate secretion in the intestine, as well as an increase in intestinal fluid secretion. Uroguanylin also stimulates sodium and water reabsorption in the kidneys, leading to an increase in urine output.
Uroguanylin has been studied for its potential therapeutic applications, particularly in the treatment of gastrointestinal disorders. For example, synthetic analogs of uroguanylin are being developed as potential treatments for constipation and other disorders of intestinal motility. Additionally, uroguanylin has been shown to have anti-inflammatory properties and may be useful in the treatment of inflammatory bowel disease.

Formula: C₆₄H₁₀₂N₁₈O₂₆S₄

Purity: Min. 95%

Molecular weight: 1,667.89 g/mol

Ref: 3D-PUG-3772-PI

Uroguanylin Isomer A (Human)

CAS: 154525-25-4

Uroguanylin is a peptide that is released by cells in the intestine. It binds to the guanylate cyclase receptor, which stimulates the production of cyclic GMP (cGMP). This leads to an increase in intestinal water and electrolyte secretion. Uroguanylin Isomer A (Human) is a high-purity peptide that can be used as a research tool for studying ligand-receptor interactions and as an inhibitor of ion channels.

Formula: C₆₄H₁₀₂N₁₈O₂₆S₄

Purity: Min. 95%

Molecular weight: 1,667.9 g/mol

Ref: 3D-PUG-4295-S

Uroguanylin Topoisomer A (human) trifluoroacetate salt

CAS: 154525-25-4

Trifluoroacetate salt

Formula: C₆₄H₁₀₂N₁₈O₂₆S₄

Purity: Min. 95%

Molecular weight: 1,667.86 g/mol

Ref: 3D-FU108618